Ironwood/Forest Talk Ballpark Pricing For Linzess, Gear Up For Q4 Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Locally-acting linaclotide wins FDA approval for two indications – chronic idiopathic constipation and constipation-predominant irritable bowel syndrome – with no limits on length of use, a development that could reinvigorate the GI space.